NCT04866134: A Study of ERAS-007 in Patients With Advanced or Metastatic Solid Tumors (HERKULES-1)

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who received previous treatment with an ERK inhibitor; Patients who received previous treatment with a MAPK inhibitor that resulted in discontinuation due to unacceptable toxicity

Comments are closed.

Up ↑